Founding & Early Platform (1987–1995)
1987: Founded; initial focus on innovative therapeutics and platform science
Early 1990s: Builds core scientific capabilities enabling later antiviral discovery and development
Mid-1990s: Pipeline orientation increasingly emphasizes antivirals
First Antiviral Breakthroughs (1996–2000)
1996: Vistide (cidofovir) FDA approval for CMV retinitis in AIDS patients; first major antiviral product
Late 1990s: Expands antiviral R&D and commercial readiness, setting up HIV-focused growth
HIV Franchise Expansion via Tenofovir Platform (2001–2005)
2001: IPO; strengthens capital base for antiviral expansion
2001: Viread (tenofovir disoproxil fumarate) approved; foundational HIV nucleotide backbone
2001: Truvada (emtricitabine/tenofovir DF) emerges as key fixed-dose combination underpinning HIV strategies
2003: Hepsera (adefovir dipivoxil) approved for chronic hepatitis B; expands beyond HIV
2004: Emtriva (emtricitabine) approved; strengthens HIV combination options
2005: Atripla (with partners) approved; accelerates once-daily single-tablet regimen uptake
Scaling HIV Leadership & Single-Tablet Regimens (2006–2010)
2006: Global scaling of HIV portfolio; expands access efforts and public health partnerships
2008: Next-wave single-tablet combination strategy forms (Complera/Eviplera-era development direction)
2009–2010: Tenofovir-based regimen adoption broadens; revenue base grows and funds larger antiviral ambitions
Transformational Acquisitions & the HCV Leap (2011–2013)
2011: Acquisition of Pharmasset; pivotal move positioning leadership in next-generation HCV therapy
2012: Stribild approved; expands HIV single-tablet leadership into integrase inhibitor–based therapy
2013: Sovaldi (sofosbuvir) approved; major HCV breakthrough enabling highly effective, shorter, oral treatment
Peak Antiviral Growth: HCV Cure Era + HIV Modernization (2014–2016)
2014: Harvoni approved; single-tablet, interferon-free HCV regimen accelerates uptake
2015: Descovy approved; introduces TAF backbone with improved renal/bone safety vs TDF for many patients
2015: Genvoya approved; migrates key HIV regimens to TAF-based formulations
2016: Epclusa approved; first broadly pangenotypic single-tablet HCV regimen simplifying treatment
Broadening Antiviral Portfolio & Long-Term HIV Strategy (2017–2019)
2017: Vosevi approved; addresses certain HCV retreatment needs, extending franchise depth
2018: Biktarvy approved; becomes a leading HIV regimen, reinforcing integrase-based single-tablet dominance
2019: Competitive environment intensifies; focus on durability, safety, and simplification to maintain HIV leadership
Antivirals in a Global Pandemic (2020–2021)
2020: Remdesivir (Veklury) receives emergency/early authorizations and broader clearances for COVID-19 treatment across jurisdictions
2020–2021: Manufacturing scale-up and global distribution become central; antiviral expertise leveraged for pandemic response
Recent Period: Portfolio Optimization & Sustained HIV Leadership (2022–Present)
2022–2024: HIV remains core growth driver via continued uptake of modern regimens (notably Biktarvy) and lifecycle management
2023–2025: Invests in next-generation modalities (longer-acting approaches, combinations, pipeline antivirals) while maintaining leadership in selective viral indications
Present: Strategy emphasizes sustaining HIV leadership, selective antiviral innovation, and balancing antiviral growth with diversification into other therapeutic areas